EP3089736A4 - Pharmazeutische zusammensetzungen für schwer wasserlösliche verbindungen - Google Patents
Pharmazeutische zusammensetzungen für schwer wasserlösliche verbindungen Download PDFInfo
- Publication number
- EP3089736A4 EP3089736A4 EP14876433.5A EP14876433A EP3089736A4 EP 3089736 A4 EP3089736 A4 EP 3089736A4 EP 14876433 A EP14876433 A EP 14876433A EP 3089736 A4 EP3089736 A4 EP 3089736A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical compositions
- poorly water
- soluble compounds
- soluble
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361922180P | 2013-12-31 | 2013-12-31 | |
| PCT/US2014/072704 WO2015103230A1 (en) | 2013-12-31 | 2014-12-30 | Pharmaceutical compositions for poorly water-soluble compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| EP3089736A1 EP3089736A1 (de) | 2016-11-09 |
| EP3089736A4 true EP3089736A4 (de) | 2017-08-23 |
| EP3089736B1 EP3089736B1 (de) | 2025-07-23 |
| EP3089736C0 EP3089736C0 (de) | 2025-07-23 |
Family
ID=53480567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14876433.5A Active EP3089736B1 (de) | 2013-12-31 | 2014-12-30 | Pharmazeutische zusammensetzungen für schwer wasserlösliche verbindungen |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20150182457A1 (de) |
| EP (1) | EP3089736B1 (de) |
| JP (1) | JP6933465B2 (de) |
| KR (2) | KR102639753B1 (de) |
| CN (2) | CN113209024A (de) |
| CA (1) | CA2935307C (de) |
| ES (1) | ES3041833T3 (de) |
| WO (1) | WO2015103230A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014121137A2 (en) | 2013-02-01 | 2014-08-07 | Glialogix, Inc. | Compositions and methods for the treatment of neurodegenerative and other diseases |
| CN106232144B (zh) * | 2014-03-18 | 2019-12-06 | 武田药品工业株式会社 | 固体分散体 |
| WO2017004733A1 (zh) * | 2015-07-03 | 2017-01-12 | 浙江海正药业股份有限公司 | 一种人参皂苷c-k口服固体制剂及其制备方法 |
| WO2017088841A1 (en) | 2015-11-26 | 2017-06-01 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| GR1009230B (el) * | 2016-10-12 | 2018-02-22 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη |
| EP3556354B1 (de) * | 2016-12-15 | 2025-05-21 | Hua Medicine (Shanghai) Ltd. | Orale herstellung eines glucokinaseaktivators und herstellungsverfahren dafür |
| CN108567743A (zh) * | 2017-03-14 | 2018-09-25 | 上海现代药物制剂工程研究中心有限公司 | 他汀类药物固体分散体、制剂及其制备方法 |
| CN106937943A (zh) * | 2017-04-20 | 2017-07-11 | 上药东英（江苏）药业有限公司 | 一种培哚普利及其盐的soluplus复合物固体分散体及其制备 |
| CN109276543B (zh) * | 2017-07-19 | 2021-01-08 | 深圳微芯生物科技股份有限公司 | 一种西格列他固体分散体及其制备方法和应用 |
| US10792249B2 (en) * | 2017-07-24 | 2020-10-06 | Acryspharm Llc | High drug loading pharmaceutical compositions |
| WO2019135725A1 (en) | 2018-01-03 | 2019-07-11 | Pisak Mehmet Nevzat | Combinations of selective cox-2 inhibitor nsaids and h2 receptor antagonists for fast treatment of pain and inflammation |
| CA3098306C (en) * | 2018-05-14 | 2024-04-16 | Capsugel Belgium Nv | Solid dosage forms with high active agent loading |
| CN112955130A (zh) | 2018-10-30 | 2021-06-11 | 佩洛通治疗公司 | 包含取代茚满的固体分散体和药物组合物及其制备和使用方法 |
| US20220017489A1 (en) * | 2018-11-02 | 2022-01-20 | Celgene Corporation | Solid dispersions for treatment of cancer |
| EP3669866A1 (de) | 2018-12-19 | 2020-06-24 | KRKA, d.d., Novo mesto | Pharmazeutische zusammensetzung mit apixaban |
| GB2584341B (en) * | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| HUE073416T2 (hu) | 2019-11-13 | 2026-01-28 | Unison Pharmaceuticals Pvt Ltd | Az apixaban orálisan dezintegrálódó gyógyszerkészítményei |
| CN113288859B (zh) * | 2020-02-21 | 2024-11-22 | 上海宣泰医药科技股份有限公司 | 奥拉帕尼药物组合物及其制剂、制备方法和用途 |
| JP7752487B2 (ja) * | 2020-03-24 | 2025-10-10 | 日本ジェネリック株式会社 | アピキサバン含有固体分散体 |
| KR102439250B1 (ko) * | 2020-07-30 | 2022-09-01 | 아주대학교산학협력단 | 실데나필 시트르산염 고체분산체의 제어방출성 경구제제 |
| CN112263567B (zh) * | 2020-10-19 | 2022-05-03 | 南京易亨制药有限公司 | 一种布洛芬缓释胶囊及制备方法 |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| CN112535665A (zh) * | 2020-12-14 | 2021-03-23 | 宁夏医科大学 | 一种格列吡嗪固体分散体及制备方法和包含其的格列吡嗪固体分散体片及制备方法 |
| CN114681419A (zh) * | 2020-12-28 | 2022-07-01 | 湖南省湘中制药有限公司 | 一种丙戊酰胺缓释片的组合物及其制备方法 |
| JP2022112698A (ja) * | 2021-01-22 | 2022-08-03 | 東和薬品株式会社 | アピキサバン含有医薬組成物 |
| CN113171344B (zh) * | 2021-04-12 | 2023-01-31 | 南京海纳医药科技股份有限公司 | 一种托伐普坦口服制剂及其制备方法 |
| US12036216B2 (en) * | 2021-06-08 | 2024-07-16 | Taho Pharmaceuticals Ltd. | Apixaban film product and uses thereof |
| NL2028762B1 (en) * | 2021-07-16 | 2023-01-23 | Seranovo Holding B V | Micelle-generating formulations for enhanced bioavailability |
| CN115300479A (zh) * | 2022-08-23 | 2022-11-08 | 宁波高新区美诺华医药创新研究院有限公司 | 奥利司他胶囊制备方法 |
| CN117717523A (zh) * | 2023-12-06 | 2024-03-19 | 佛山科学技术学院 | 一种替米考星肠道定位缓释剂及其制备方法 |
| CN118845677B (zh) * | 2024-07-09 | 2025-10-10 | 常州大学 | 一种阿霉素无定形固体分散体及其制备方法和应用 |
| US12605388B2 (en) | 2024-09-25 | 2026-04-21 | Azurity Pharmaceuticals Ireland Limited | Lamotrigine salts, co-crystals, and compositions |
| CN119606886B (zh) * | 2025-01-09 | 2025-10-17 | 成都苑东生物制药股份有限公司 | 一种奥沙西泮的药物组合物 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026461A2 (en) * | 2007-08-21 | 2009-02-26 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| DE102009036646A1 (de) * | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
| US20110306632A1 (en) * | 2010-06-09 | 2011-12-15 | Abbott Laboratories | Solid Dispersions Containing Kinase Inhibitors |
| WO2013040120A1 (en) * | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2528706B2 (ja) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
| WO1992018106A1 (fr) | 1991-04-16 | 1992-10-29 | Nippon Shinyaku Co., Ltd. | Procede de production d'une dispersion solide |
| CA2450748A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
| JP2004067606A (ja) * | 2002-08-08 | 2004-03-04 | Zensei Yakuhin Kogyo Kk | イトラコナゾール経口投与製剤 |
| CA2645566A1 (en) * | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
| JP2011515444A (ja) * | 2008-03-25 | 2011-05-19 | フォーマック ファーマシューティカルズ ナムローゼ フェンノートシャップ | 固体分散体の調製方法 |
| US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
| JP5847813B2 (ja) * | 2010-06-23 | 2016-01-27 | シマベイ セラピューティクス， インコーポレーテッド | ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物 |
| EP2755637B1 (de) * | 2011-09-13 | 2020-08-12 | ISP Investments LLC | Feste dispersion aus schwerlöslichen verbindungen mit crospovidon und mindestens einem wasserlöslichen polymer |
| US20130172375A1 (en) * | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
-
2014
- 2014-12-30 EP EP14876433.5A patent/EP3089736B1/de active Active
- 2014-12-30 CA CA2935307A patent/CA2935307C/en active Active
- 2014-12-30 US US14/585,700 patent/US20150182457A1/en not_active Abandoned
- 2014-12-30 WO PCT/US2014/072704 patent/WO2015103230A1/en not_active Ceased
- 2014-12-30 CN CN202110140047.8A patent/CN113209024A/zh active Pending
- 2014-12-30 KR KR1020227005384A patent/KR102639753B1/ko active Active
- 2014-12-30 KR KR1020167021048A patent/KR20160104709A/ko not_active Ceased
- 2014-12-30 JP JP2016541707A patent/JP6933465B2/ja active Active
- 2014-12-30 CN CN201480075504.8A patent/CN106456539B/zh active Active
- 2014-12-30 ES ES14876433T patent/ES3041833T3/es active Active
-
2017
- 2017-05-10 US US15/591,829 patent/US20170252332A1/en not_active Abandoned
-
2019
- 2019-06-17 US US16/443,324 patent/US20200009125A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009026461A2 (en) * | 2007-08-21 | 2009-02-26 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| DE102009036646A1 (de) * | 2009-08-07 | 2011-02-10 | Ratiopharm Gmbh | Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon |
| US20110306632A1 (en) * | 2010-06-09 | 2011-12-15 | Abbott Laboratories | Solid Dispersions Containing Kinase Inhibitors |
| WO2013040120A1 (en) * | 2011-09-14 | 2013-03-21 | Celgene Corporation | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2015103230A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015103230A1 (en) | 2015-07-09 |
| EP3089736B1 (de) | 2025-07-23 |
| JP6933465B2 (ja) | 2021-09-08 |
| ES3041833T3 (en) | 2025-11-14 |
| EP3089736C0 (de) | 2025-07-23 |
| KR20220027268A (ko) | 2022-03-07 |
| JP2017500349A (ja) | 2017-01-05 |
| KR102639753B1 (ko) | 2024-02-22 |
| US20150182457A1 (en) | 2015-07-02 |
| CN106456539B (zh) | 2021-02-26 |
| CN106456539A (zh) | 2017-02-22 |
| KR20160104709A (ko) | 2016-09-05 |
| EP3089736A1 (de) | 2016-11-09 |
| CA2935307C (en) | 2023-05-09 |
| US20200009125A1 (en) | 2020-01-09 |
| WO2015103230A9 (en) | 2015-10-22 |
| CA2935307A1 (en) | 2015-07-09 |
| CN113209024A (zh) | 2021-08-06 |
| US20170252332A1 (en) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3089736A4 (de) | Pharmazeutische zusammensetzungen für schwer wasserlösliche verbindungen | |
| IL288961A (en) | Pharmaceutical preparations | |
| EP3082817A4 (de) | Zusammensetzungen zur arzneimittelverabreichung | |
| EP3129028A4 (de) | Pharmazeutische zusammensetzungen | |
| PL2943181T3 (pl) | Kompozycje farmaceutyczne | |
| EP3104860A4 (de) | Pharmazeutische verbindungen | |
| EP3016667A4 (de) | Orale zusammensetzungen | |
| ZA201408333B (en) | Pharmaceutical compositions | |
| EP3085385A4 (de) | Pharmazeutische zusammensetzung mit adalimumab | |
| EP3160491A4 (de) | Pharmazeutische zusammensetzungen | |
| EP2990039A4 (de) | Feste pharmazeutische zusammensetzung | |
| EP3003324A4 (de) | Pharmazeutische zusammensetzungen | |
| EP3003369A4 (de) | Pharmazeutische zusammensetzungen mit pyrophosphat | |
| EP2968256A4 (de) | Budiodaron-formulierungen | |
| EP3191093A4 (de) | Pharmazeutische zusammensetzungen | |
| EP3189033A4 (de) | Pharmazeutische verbindungen | |
| EP2844230B8 (de) | Pharmazeutische zusammensetzungen zur direkten systemischen einführung | |
| EP3043648A4 (de) | Pharmazeutische bendamustinzusammensetzungen | |
| EP3041478A4 (de) | Impfstoffzusammensetzungen für drogenabhängigkeit | |
| EP2992890A4 (de) | Pharmazeutische zusammensetzung | |
| EP3082783A4 (de) | Stabile orale pharmazeutische zusammensetzung | |
| AP2015008890A0 (en) | Pharmaceutical compositions | |
| EP3188726A4 (de) | Pharmazeutische verbindungen | |
| HK1230932A1 (en) | Pharmaceutical compositions for poorly water-soluble compounds | |
| GB201304699D0 (en) | Pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160728 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170721 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/14 20060101ALI20170717BHEP Ipc: A61K 47/30 20060101ALI20170717BHEP Ipc: A61K 47/38 20060101AFI20170717BHEP |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1230932 Country of ref document: HK |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20190507 |
|
| TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20250213 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014092180 Country of ref document: DE |
|
| U01 | Request for unitary effect filed |
Effective date: 20250821 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250829 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3041833 Country of ref document: ES Kind code of ref document: T3 Effective date: 20251114 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20251123 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20251023 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20251024 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20251023 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250723 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250723 |